Viral Vectors Mapped: New Insights into Gene Therapy’s Infectious Footprint
A recent study in Gene Therapy leverages advanced spatial transcriptomics and single-nucleus RNA sequencing to define the precise host–pathogen interactions and transmission dynamics of recombinant adeno-associated viruses (rAAVs) in the mouse liver. The research, published in March 2026, reveals distinct viral infection and cellular transduction signatures specific to rAAV2 and rAAV9 serotypes. This high-resolution mapping provides a critical understanding of how these common gene therapy vectors interact with host tissues at a molecular level, offering a new lens on the infection control parameters for therapeutic viral delivery.
Study Significance: For professionals focused on viral infections and therapeutic development, this work provides a foundational model for assessing the safety and tropism of viral vectors, a cornerstone of modern gene therapy and vaccination platforms. The methodologies established here could be directly applied to the study of emerging pathogens and zoonotic infections, enhancing pandemic preparedness by improving our ability to predict and monitor viral behavior in host systems. This research shifts the strategic approach to vector design from empirical to predictive, enabling more targeted and safer clinical applications.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
